Celldex Therapeutics
CLDX
162 hedge funds and large institutions have $1.85B invested in Celldex Therapeutics in 2013 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 59 increasing their positions, 47 reducing their positions, and 24 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
58% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 24
37% more call options, than puts
Call options by funds: $42M | Put options by funds: $30.7M
26% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 47
8% more funds holding
Funds holding: 150 → 162 (+12)
19% less capital invested
Capital invested by funds: $2.28B → $1.85B (-$431M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$90.2M |
| 2 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$51.8M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$42.9M |
| 4 |
O
OrbiMed
New York
|
+$33.7M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$29.6M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$23.8M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$16.1M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$13.3M |
| 5 |
First Eagle Investment Management
New York
|
-$10.7M |
CLDX Hedge Fund Activity: Q4 2013 in Review
162 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2013, worth a combined $1.85B — down 19% from $2.28B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new CLDX positions and 24 closed out — a net gain of 14 holders — while 59 added to existing stakes and 47 trimmed.
The largest buyer was OppenheimerFunds, adding an estimated $90.2M. The largest seller was BlackRock Advisors, cutting an estimated $29.6M.
- 162 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2013, up from 150 in Q3 2013.
- Funds reported $1.85B of Celldex Therapeutics stock for Q4 2013, down 19% quarter-over-quarter.
- 38 funds opened new Celldex Therapeutics positions in Q4 2013 and 24 closed out, a net change of +14 holders.
- The largest Celldex Therapeutics buyer in Q4 2013 was OppenheimerFunds, an estimated $90.2M added.
- The largest Celldex Therapeutics seller in Q4 2013 was BlackRock Advisors, an estimated $29.6M sold.
Based on aggregated 13F filings for Q4 2013.